Routinely collected electronic health records using artificial intelligence (AI)-based systems bring out enormous benefits for patients, healthcare centers, and its industries. Artificial intelligence models can be used to structure a wide variety of unstructured data. We present a semi-automatic workflow for medical dataset management, including data structuring, research extraction, AI-ground truth creation, and updates. The algorithm creates directories based on keywords in new file names. Our work focuses on organizing computed tomography (CT), magnetic resonance (MR) images, patient clinical data, and segmented annotations. In addition, an AI model is used to generate different initial labels that can be edited manually to create ground truth labels. The manually verified ground truth labels are later included in the structured dataset using an automated algorithm for future research. This is a workflow with an AI model trained on local hospital medical data with output based/adapted to the users and their preferences. The automated algorithms and AI model could be implemented inside a secondary secure environment in the hospital to produce inferences.

Automated algorithms for liver parenchyma segmentation can be used to create patient-specific models (PSM) that assist clinicians in surgery planning. In this work, we analyze the clinical applicability of automated deep learning methods together with level set post-processing for liver segmentation in contrast-enhanced T1-weighted magnetic resonance images. UNet variants with/without attention gate, multiple loss functions, and level set post-processing were used in the workflow. A multi-center, multi-vendor dataset from Oslo laparoscopic versus open liver resection for colorectal liver metastasis clinical trial is used in our study. The dataset of 150 volumes is divided as 81:25:25:19 corresponding to train:validation:test:clinical evaluation respectively. We evaluate the clinical use, time to edit automated segmentation, tumor regions, boundary leakage, and over-and-under segmentations of predictions. The deep learning algorithm shows a mean Dice score of 0.9696 in liver segmentation, and we also examined the potential of post-processing to improve the PSMs. The time to create clinical use segmentations of level set post-processed predictions shows a median time of 16 min which is 2 min less than deep learning inferences. The intra-observer variations between manually corrected deep learning and level set post-processed segmentations show a 3% variation in the Dice score. The clinical evaluation shows that 7 out of 19 cases of both deep learning and level set post-processed segmentations contain all required anatomy and pathology, and hence these results could be used without any manual corrections. The level set post-processing reduces the time to create clinical standard segmentations, and over-and-under segmentations to a certain extent. The time advantage greatly supports clinicians to spend their valuable time with patients.

Percutaneous interventions are gaining rapid acceptance in cardiology and revolutionizing the treatment of structural heart disease (SHD). As new percutaneous procedures of SHD are being developed, their associated complexity and anatomical variability demand a high-resolution special understanding for intraprocedural image guidance. During the last decade, three-dimensional (3D) transesophageal echocardiography (TEE) has become one of the most accessed imaging methods for structural interventions. Although 3D-TEE can assess cardiac structures and functions in real-time, its limitations (e.g., limited field of view, image quality at a large depth, etc.) must be addressed for its universal adaptation, as well as to improve the quality of its imaging and interventions. This review aims to present the role of TEE in the intraprocedural guidance of percutaneous structural interventions. We also focus on the current and future developments required in a multimodal image integration process when using TEE to enhance the management of congenital and SHD treatments.